Other equities analysts have also recently issued reports about the company. Barclays dropped their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, September 12th. Robert W. Baird increased their target price on IQVIA from $260.00 to $265.00 in a report on Friday, July 22nd. Evercore ISI increased their target price on IQVIA from $265.00 to $275.00 in a report on Friday, July 22nd. Argus raised their price target on IQVIA from $260.00 to $275.00 in a report on Thursday, August 18th. Finally, SVB Leerink started coverage on IQVIA in a report on Friday, July 15th. They set an “outperform” rating and a $256.00 price target for the company. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.00.
IQVIA Price Performance
Shares of NYSE:IQV opened at $199.66 on Wednesday. The business has a 50 day moving average price of $224.67 and a 200 day moving average price of $220.57. IQVIA has a twelve month low of $194.67 and a twelve month high of $285.61. The company has a market cap of $37.24 billion, a price-to-earnings ratio of 33.33, a PEG ratio of 1.87 and a beta of 1.34. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 2.36.
Institutional Trading of IQVIA
Hedge funds and other institutional investors have recently modified their holdings of the stock. Riverview Trust Co bought a new stake in shares of IQVIA during the first quarter worth approximately $25,000. Knott David M Jr bought a new stake in shares of IQVIA in the second quarter valued at approximately $26,000. Dividend Assets Capital LLC bought a new stake in shares of IQVIA in the first quarter valued at approximately $27,000. Johnson Financial Group Inc. bought a new stake in shares of IQVIA in the fourth quarter valued at approximately $34,000. Finally, Quent Capital LLC raised its position in IQVIA by 271.8% during the first quarter. Quent Capital LLC now owns 145 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 86.77% of the company’s stock.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.